title: Inhibition of prolactin-induced mammary cancer in C3Hf (XVII) mice with the trans isomer of bromotriphenylethylene.
abstract: C3Hf (XVII) mice never develop spontaneous mammary tumors. However, the transplantation of an isologous pituitary gland under their kidney capsule is followed by a 10-fold increase in serum and pituitary prolactin content (180 ng/ml and 20 micrograms/mg of tissue, respectively), concomitant with an increase of prolactin receptors in mammary glands. Under these conditions, mammary tumors appear in 90% of the mice. If a racemic brominated triphenylethylene, i.e., broparestrol, is administered, serum and pituitary prolactin decrease rapidly (10 ng/ml and 4 micrograms/mg of tissue, respectively), and prolactin receptors in the mammary gland are markedly reduced. This compound also inhibits the development of normal mammary glands, prevents mammary carcinogenesis, and unexpectedly causes a significant atrophy of the ovaries. Our study confirms that prolactin is a key hormone involved in murine mammary carcinogenesis and that it can act directly on the mammary gland by stimulaing the level of its own receptor.
mesh_terms: D000818:Animals; D005260:Female; D008325:Mammary Neoplasms, Experimental / Q000139:chemically induced*; D051379:Mice; D008809:Mice, Inbred C3H; D010902:Pituitary Gland / Q000637:transplantation; D011388:Prolactin / Q000037:antagonists & inhibitors / Q000097:blood; D011956:Receptors, Cell Surface / Q000378:metabolism; D013237:Stereoisomerism; D013267:Stilbenes / Q000494:pharmacology*
chemical_list: D011956:Receptors, Cell Surface; D013267:Stilbenes; C004507:broparoestrol; D011388:Prolactin